Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SYN818 With Olaparib in Patients With Locally Advanced or Metastatic Solid Tumors

NCT07156253 is registered in ClinicalTrials.gov with Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd as lead sponsor.

NCT NCT07156253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07156253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SYN818 With Olaparib in Patients With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
August 26, 2025
Completion date
February 25, 2029
Enrollment
110 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, brca 1 /2 and / or hrd, breast cancer, metastatic solid tumor, ovarian cancer